ArticleScience translational medicine2017
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 98 citations in OpenAlex.
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- GLYCO-BUILD: an enzymatic pipeline for the synthesis of peptides carrying eukaryotic N-glycans.Nature communications · 2025Article
- Article
- Repeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenic E. coli adhesin.PLoS pathogens · 2024Article
- Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen Vaccine Delivery.Bioconjugate chemistry · 2024Article
- SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition.Molecular cell · 2024Article
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell host & microbe · 2024Article
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell host & microbe · 2024Article
- Repeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenicbioRxiv : the preprint server for biology · 2024Article
- Prophylactic HIV-1 vaccine trials: past, present, and future.The lancet. HIV · 2024Review
- Bringing immunofocusing into focus.NPJ vaccines · 2024Review
- Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.Cell · 2024Article
- Broadly neutralizing antibodies targeting HIV: Progress and challenges.Clinical immunology (Orlando, Fla.) · 2023Review
- Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.Nature reviews. Immunology · 2023Review
- Large-Scale Synthesis of ManACS infectious diseases · 2022Article
- Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.Chemical reviews · 2022Review
- Synthesis of glycopeptides and glycopeptide conjugates.Organic & biomolecular chemistry · 2022Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 9 institutions in 2 countries.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0941-0703
Baptiste AussedatDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-8828-8963
Yusuf VohraDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-0385-2965
R Ryan MeyerhoffDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-1253-2250
Evan M CaleVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-9176-8263
William E WalkowiczDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7961-1175
Nathan A RadakovichVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Kara AnastiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1854-743X
Lawrence ArmandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Laura SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-4119-3884
Richard ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
M Gordon JoyceVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-6808-7232
Marie PanceraVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Aliaksandr DruzVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ivelin S GeorgievVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Tarra Von HolleDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-8690-9095
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-3064-2947
Christopher FoxInfectious Disease Research Institute, Seattle, WA 98102, USA.
Steven G ReedInfectious Disease Research Institute, Seattle, WA 98102, USA.ORCID 0000-0003-2193-100X
Mark LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7540-9263
Robert T BailerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lynn MorrisNational Institute for Communicable Diseases, Johannesburg 2131, South Africa.ORCID 0000-0003-3961-7828
Salim S Abdool-KarimNational Institute for Communicable Diseases, Johannesburg 2131, South Africa.ORCID 0000-0002-4986-2133
Myron CohenDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5917-9664
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Peter K ParkDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Alberto Fernández-TejadaDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-1680-0059
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Sampa SantraBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Thomas B KeplerDepartment of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA.ORCID 0000-0002-1383-6865
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Joseph SodroskiDana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.ORCID 0000-0002-9750-1615
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3560-232X
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2973-2101
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-3890-5855
Samuel DanishefskyDepartment of Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-2847-1854
Duke University · USNational Institutes of Health · USMemorial Sloan Kettering Cancer Center · USCentre for the AIDS Programme of Research in South Africa · ZAInfectious Disease Research Institute · USBeth Israel Deaconess Medical Center · USBoston University · USHarvard University · USUniversity of North Carolina at Chapel Hill · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2017 to 2026
$40.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MDesign Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MHIV, TB, and Malaria Vaccine Development for AfricaP01AI052816 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2003 to 2007
$14.5MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MRational Immunogen Design Using Computational MethodsZICAI005114 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2010 to 2025
$4.3MNovel mouse model of HIV broad neutralizing antibody inductionF30AI122982 · NIAID · DUKE UNIVERSITY · PI MEYERHOFF, ROBERT RYAN · 2016 to 2017
$79kNIAID NIH HHS F30 AI122982NIAID NIH HHS P01 AI052816NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI120801NIAID NIH HHS UM1 AI100645NIGMS NIH HHS T32 GM007171
Abstract
A goal for an HIV-1 vaccine is to overcome virus variability by inducing broadly neutralizing antibodies (bnAbs). One key target of bnAbs is the glycan-polypeptide at the base of the envelope (Env) third variable loop (V3). We have designed and synthesized a homogeneous minimal immunogen with high-mannose glycans reflective of a native Env V3-glycan bnAb epitope (Man
Indexed as
AnimalsAntibodies, NeutralizingAntibody SpecificityB-LymphocytesCell LineageCell SeparationClone CellsEpitopesGlycopeptidesHIV-1HIV AntigensHIV Envelope Protein gp120Macaca mulattaMolecular MimicryProtein DomainsProtein MultimerizationAntibodies, NeutralizingEpitopesGlycopeptidesHIV AntigensHIV Envelope Protein gp120
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.